News in brief - October 2013

Other new launches, licence changes and updates relevant to general practice.

by
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment  of type II diabetes.
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment of type II diabetes.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package